Reimagining RNA medicine

Sep 30, 2024

Wave Life Sciences to Present at Chardan 8th Annual Genetic Medicines Conference

Sep 25, 2024

Wave Life Sciences Prices Upsized $200 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

Sep 24, 2024

Wave Life Sciences Announces Proposed Public Offering of Ordinary Shares and Pre-Funded Warrants

Sep 24, 2024

Wave Life Sciences Announces Positive Interim Data from FORWARD-53 Clinical Trial Evaluating WVE-N531 in Boys with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping

Aug 12, 2024

Wave Life Sciences Receives FDA Rare Pediatric Disease Designation for WVE-N531 for the Treatment of Duchenne Muscular Dystrophy

Aug 08, 2024

Wave Life Sciences Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 01, 2024

Wave Life Sciences Second Quarter 2024 Financial Results Scheduled for August 8, 2024

Jun 25, 2024

Wave Life Sciences Announces Positive Results from Phase 1b/2a SELECT-HD Trial with First Clinical Demonstration of Allele-Selective Mutant Huntingtin Lowering in Huntington’s Disease

Jun 12, 2024

Wave Life Sciences Announces Upcoming Presentations Highlighting Novel siRNA Program in Obesity and Leadership in RNA Editing

May 30, 2024

Wave Life Sciences to Present at 2024 Jefferies Global Healthcare Conference